US drug developer Apellis Pharmaceuticals (Nasdaq: APLS) was upbeat about clinical trial results for its pegcetacoplan, but investors thought otherwise, sending the firm’s shares down 32% to $38.00 in after hours on Thursday.
Apellis announced top-line results from the Phase III DERBY and OAKS studies evaluating intravitrealb pegcetacoplan, an investigational targeted C3 therapy, in 1,258 adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). GA is a leading cause of blindness that impacts more than five million people globally including one million people in the USA>
Based on results from the studies, the company plans to submit a New Drug Application (NDA) for pegcetacoplan for GA to the US Food and Drug Administration (FDA) in the first half of 2022.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze